Humacyte, a clinical-stage biotechnology platform company, announced the issuance of three additional US patents covering its proprietary technology platform. Included in the new patents are additional claims related to the Human Acellular Vessels (HAVs), engineered, off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement.
New US Patents 10,934,532 and 10,947,498, both titled “Tissue-engineered constructs,” expand upon existing patents encompassing methods of producing the Company’s HAVs and other human tissues, including the scaffolds and methods used to make these product candidates. New US Patent 11,058,534, titled “Tubular prothesis,” covers biologic replacements for diseased or damaged anatomical conduits, including the trachea.
For issued US patents, the last patent expires in 2035 and additional US patent applications pending, if issued, would extend coverage into 2040. US Patents 10,934,532 and 10,947,498 are owned directly by Humacyte. US Patent 11,058,534 is jointly owned by Humacyte and Yale University, and Yale has exclusively licensed its rights to Humacyte.
In addition to the US patents, an additional 23 international patents were issued covering the scaffolds used to make Humacyte’s vessels, the composition of the vessels, and systems and methods of manufacturing the vessels. Humacyte now owns or licenses a total of 14 US patents and 105 international patents covering its proprietary platform.
“We continue to look for means to expand the protection of our proprietary technology platform through pursuing the patent of new inventions and improvements, whether developed internally or in cooperation with our collaborators,” said Laura Niklason, M.D., Ph.D., founder, president and chief executive officer. “We are pleased with the recent expansion of our patent estate and thank our internal team and key collaborators who have made this exceptional progress possible.”
Human Acellular Vessels (HAV) is engineered off-the-shelf replacement vessels initially being developed for vascular repair, reconstruction and replacement. HAV is intended to overcome long-standing limitations in vessel tissue repair and replacement – it can be manufactured at commercial scale, it eliminates the need for harvesting a vessel from a patient, and clinical evidence suggests that it is non-immunogenic, infection-resistant, and can become durable living tissue
